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Abstract
Background: Randomized controlled trials (RCTs) form the foundational background of modern medical practice.
They are considered the highest quality of evidence, and their results help inform decisions concerning drug
development and use, preventive therapies, and screening programs. However, the inputs that justify an RCT to
be conducted have not been studied.
Methods: We reviewed the MEDLINE and EMBASE databases across six specialties (Ophthalmology, Otorhinolaryngology
(ENT), General Surgery, Psychiatry, Obstetrics-Gynecology (OB-GYN), and Internal Medicine) and randomly chose
25 RCTs from each specialty except for Otorhinolaryngology (20 studies) and Internal Medicine (28 studies). For
each RCT, we recorded information relating to the justification for conducting RCTs such as average study size cited,
number of studies cited, and types of studies cited. The justification varied widely both within and between specialties.
Results: For Ophthalmology and OB-GYN, the average study sizes cited were around 1100 patients, whereas they were
around 500 patients for Psychiatry and General Surgery. Between specialties, the average number of studies cited
ranged from around 4.5 for ENT to around 10 for Ophthalmology, but the standard deviations were large, indicating
that there was even more discrepancy within each specialty. When standardizing by the sample size of the RCT, some
of the discrepancies between and within specialties can be explained, but not all. On average, Ophthalmology papers
cited review articles the most (2.96 studies per RCT) compared to less than 1.5 studies per RCT for all other specialties.
Conclusions: The justifications for RCTs vary widely both within and between specialties, and the justification for
conducting RCTs is not standardized.
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Background
Randomized controlled trials (RCTs) are often the
cornerstone for deciding whether a specific medical
intervention is used, yet there has not been much
research concerning why each particular trial is con-
ducted. As the name suggests, a randomized controlled
trial is a trial where subjects are randomized to differ-
ent groups, and after the intervention, the outcomes of
the different groups are compared [1]. Randomizing the
subjects ensures that, on average, other possible causes
of the outcome are balanced between the groups and
any significant differences between the outcomes of the
different groups can be attributed to the intervention
[2]. This helps to minimize bias and confounding in
the trial.
Other than randomization, another essential component
of an RCT is the control aspect. In a typical RCT, the
outcomes of the intervention group are compared to a
control group [3], where the intervention group receives
the intervention and the control group receives no inter-
vention or the current best practice intervention.
Since RCTs allow scientists and clinicians to make
causal inferences between an intervention and its
outcome, RCTs are one of the strongest forms of
evidence for determining an intervention’s efficacy [3].
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In evidence-based medicine, RCTs (and their system-
atic reviews) are positioned at the top of the hierarchy
in terms of evidence used to guide medical decisions
[4]. Not surprisingly, they are a staple of government
regulatory bodies for decision making concerning drug
applications to market.
Properly conducted RCTs can minimize bias and
provide, as closely as possible, a definitive answer to the
effectiveness of an intervention. With such an important
type of evidence, naturally, there are rules for how to
report the design and results of RCTs. While there are
different guidelines available, the most commonly used
and recommended is the Consolidated Standards of
Reporting Trials (CONSORT) [5]. The CONSORT state-
ment has recommendations for the reporting of every
aspect of RCTs [5].
The conduct of an RCT, its reporting, and subsequent
syntheses are well formalized, but the upstream process
of any particular RCT is not formalized at all. There are
typically two components to this upstream process. The
“PICO” component (patient, intervention, comparison,
outcome) is the creative process whereby the idea and
the skeleton of the study are generated. The second
upstream component we term “justification.” Justifica-
tion is the body of previous information that allows for
the conduct of an RCT given the need to justify issues of
ethics, equipoise, and costs. The focus of this paper is to
compare the upstream justification of RCTs both within
and across different medical areas. Specifically, this
paper will focus on what is recommended in the Intro-
duction as the aim is to understand the justification for
an RCT to be conducted.
Important information related to the scientific back-
ground and justification for the RCT should be included
in the Introduction section of an RCT including any
background or previous evidence for the benefits or
harms of the interventions being studied in that particu-
lar trial [5]. One would also expect that the justification
for conducting an RCT should be fairly uniform both
within and across medical fields. In other words, one
would expect that the justification for an RCT should be
as uniform as its conduct, reporting, and subsequent
syntheses.
Since RCTs are an important part of decision making
for medical interventions, there should be a solid foun-
dation and underlying evidence for an RCT to be con-
ducted. With the increased regulations surrounding the
conduct of RCTs, there have been increased costs asso-
ciated with performing these trials [6]. Since RCTs are
expensive to conduct, care should be taken to ensure
that only relevant RCTs are performed. This means that
there should be enough background evidence to justify
the RCT, and one would hope for some sort of uni-
formity in RCT justification in general. Having an idea
to answer a clinical question is not enough to justify
conducting a RCT; there needs to be sufficient evidence
in order to avoid conducting RCTs that waste money
and unnecessarily place patients at risk.
RCTs are an essential part of decision making, so they
should only be conducted when there is a solid base of
evidence supporting their conduct. The present litera-
ture is very sparse at studying the reasons for why any
particular RCT is being done. To formally study this
question, this paper will quantify and summarize what
types of evidence are cited in the Introduction as the
reason for the RCT to be performed.
Methods
Study inclusion criteria
A literature search was conducted between January 2015
and July 2015 to identify randomized controlled trials
(RCTs) published between January 2014 and July 2015 from
the fields of Ophthalmology, Obstetrics and Gynecology
(OB-GYN), Otorhinolaryngology (ENT), Internal Medicine,
General Surgery, and Psychiatry.
Primary studies focusing on modeling or adverse
events only were excluded, as were studies that included
20 or fewer participants. In addition, primary articles de-
scribing results from more than one trial were excluded.
Search strategy
The search was conducted through OVID in the follow-
ing databases: MEDLINE, EMBASE, and the Cochrane
Central Register of Controlled Trials. The medical fields
of concern were specified by exploding MeSH headings.
A list of search terms used to search for articles in each
field is provided in Additional file 1.
Study selection
A random sample of 20–30 studies was chosen for data
extraction in each medical field. Each study that was
found through the search strategy was given a unique ID
number. A complete list of unique ID numbers was then
generated for each medical field in Microsoft Excel, and
those studies were evaluated for the inclusion criteria. If
a study did not meet the inclusion criteria, the next
number in the list was evaluated for inclusion.
Screening and data extraction
Two-level screening was performed by two reviewers —
first with abstracts alone (level 1) and then with full-text
articles (level 2). For the selected primary articles, basic
study characteristics and patient demographics were col-
lected: journal, print date, study objective, country of
origin (as defined by primary author location), number
of participants enrolled and the number completed,
mean age of participants, gender (percentage of male
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participants), and race ethnicity (percentage of Cauca-
sian participants).
Most importantly, the references in each study’s Intro-
duction were examined. Only references used to justify
conducting the RCT were included in data extraction.
The references were categorized by the type of study.
The sample size of the study referenced was recorded as
well.
References were excluded if they discussed an earlier
publication of the current trial or if they focused on
topics peripheral to the study objective. References to
descriptive information about the drug or condition be-
ing studied were also excluded.
The categories used for reference extraction were as
follows: cited expert opinion, review articles, case re-
ports or case series, case control studies, cohort studies,
cross-sectional studies, and randomized controlled trials.
For expert opinion and review articles, the sample size
was not recorded.
To ensure consistent methodology, data extraction
was performed by a primary reviewer and edited/con-
firmed by a secondary reviewer. Data extraction was per-
formed by authors JC and KL, and disagreements were
refereed by WH. Extracted data were recorded in an
Excel spreadsheet.
Results
Using the search strategy described above, the following
numbers of RCTs for each specialty were found:
Ophthalmology (156), OB-GYN (99), Psychiatry (81),
General Surgery (113), ENT (27), and Internal Medicine
(1016). Twenty-five RCTs were randomly selected from
each specialty using the RANDOM function in Micro-
soft Excel. However, only 20 RCTs from ENT were in-
cluded in the analysis due to the lack of RCTs meeting
inclusion/exclusion criteria, and 28 RCTs from Internal
Medicine were included due to the need to select an
equal number of studies from each of the seven subspe-
cialties for Internal Medicine (Cardiology, Endocrinology,
Gastroenterology, Hematology, Nephrology, Pulmonology,
and Rheumatology).
Table 1 outlines the patient demographics from the
RCTs used (not the cited studies). The lowest average
age was found in Psychiatry studies (39.1 years), with In-
ternal Medicine, Ophthalmology, and General Surgery
having higher average age patients, typically in their
mid-50s. ENT had 70% males in their RCT studies; of
course, OB-GYN had 100% females. The rest of the
specialties had close to a 50/50 split between genders.
Approximately three quarters of the studies across all
specialties had Caucasians as the predominant race for
participants.
Figure 1 shows the average total number of studies
cited per specialty to justify the present published RCT.
ENT had the lowest number of cited studies at 4.5 and
Ophthalmology the highest at 10.0. While this is more
than a twofold range, the discrepancy within specialties
was even greater. For example, in Ophthalmology, as
few as 2 articles were cited to justify some RCTs and as
many as 27 to justify others. Clearly, both within and
across medical areas, the number of cited studies used
to justify an RCT varies widely.
Table 2 summarizes the average number of studies
cited per RCT in each specialty and also breaks this
number down by study type. Cohort studies would typic-
ally be considered the highest quality evidence after
RCTs. There was again a large range difference for co-
hort studies cited between medical fields and an even
larger range within medical fields. Between medical
fields, Obstetrics/Gynecology RCTs cite on average 0.2
cohort studies per RCT done and Internal Medicine
RCTs cite 1.3 cohort studies per RCT done, which is
more than a sixfold difference. Within medical spe-
cialties, the range is large and the standard deviation
is always larger than the mean, indicating a very large







Ophthalmology AVERAGE 58.3 44.7 78.2
Std. Dev. 13.3 16.0 14.9
Maximum 80.0 100 96.8
Minimum 36.7 24.1 53.1
Obstetrics and Gynecology AVERAGE 45.7 0 75.0
Std. Dev. 16.0 0 28.5
Maximum 63.7 0 97.1
Minimum 23.0 0 0
Psychiatry AVERAGE 39.1 50.7 75.6
Std. Dev. 17.7 22.4 14.5
Maximum 75.5 100 97.0
Minimum 8.8 0 50.8
General Surgery AVERAGE 57.0 51.7 81.5
Std. Dev. 11.5 24.4 15.8
Maximum 78.1 80.5 96.4
Minimum 38.0 0 49.2
Otorhinolaryngology AVERAGE 43.9 69.6 73.0
Std. Dev. 16.7 18.7 29.4
Maximum 64.8 96.8 97.9
Minimum 7.2 25.0 0
Internal Medicine AVERAGE 53.2 53.9 76.4
Std. Dev. 17.6 20.2 15.8
Maximum 71.5 78.3 98.0
Minimum 6.1 0.1 47.5
Std. Dev. standard deviation
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discrepancy in the type of study cited within medical
areas.
The average size of studies cited also varies widely. It
should be noted that in all medical areas, it is quite com-
mon to cite population-based studies as reasons to
justify RCTs; hence, the average study sizes tend to be
large across all fields. However, the differences are again
very marked. Figure 2 summarizes this data. The average
ENT study cited involved 399 participants, while in In-
ternal Medicine the size was 3238 patients, an eightfold
Fig. 1 Average number of studies cited to justify RCTs stratified by specialty
Table 2 Total number of studies cited to justify RCTs stratified by specialty and study type
Specialty Total papers Case series Case controls Cohort studies Cross sectional RCTs Expert opinion Review articles
Ophthalmology AVERAGE 10 1.16 0.24 1.1 0.68 3.52 0.24 2.96
Std. Dev. 6.6 2 0.83 1.5 1.35 3.83 0.52 2.42
Maximum 27 9 4 5 5 18 2 7
Minimum 2 0 0 0 0 0 0 0
OB-GYN AVERAGE 4.8 1.7 0 0.2 0.04 1.96 0.12 0.68
Std. Dev. 3.2 2.4 0 0.5 0.2 2.13 0.33 1.07
Maximum 12 8 0 2 1 7 1 4
Minimum 0 0 0 0 0 0 0 0
Psychiatry AVERAGE 4.8 0.24 0.04 0.4 0.36 2.52 0.04 1.16
Std. Dev. 3.1 0.66 0.2 1.4 0.99 2.02 0.2 1.46
Maximum 12 3 1 7 4 7 1 5
Minimum 0 0 0 0 0 0 0 0
General Surgery AVERAGE 8.8 2 0.16 0.88 0.16 3.64 0.6 1.40
Std. Dev. 4.5 2 0.47 0.88 0.47 3.17 1.08 1.41
Maximum 21 7 2 3 2 12 4 6
Minimum 4 0 0 0 0 0 0 0
ENT AVERAGE 4.5 0.95 0.05 0.25 0.15 1.85 0.05 1.05
Std. Dev. 2.8 1.1 0.22 0.91 0.49 2.25 0.22 1.36
Maximum 11 4 1 4 2 9 1 5
Minimum 0 0 0 0 0 0 0 0
Internal Medicine AVERAGE 7.5 0.93 0.21 1.29 0.39 3.18 0.25 1.11
Std. Dev. 4.2 1.6 0.69 2.42 0.99 3.24 0.65 1.07
Maximum 19 7 3 10 4 10 3 3
Minimum 2 0 0 0 0 0 0 0
RCT randomized controlled trial, Std. Dev. standard deviation, OB-GYN Obstetrics and Gynecology, ENT Otorhinolaryngology
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difference. And within Internal Medicine, the range var-
ies from 34 patients to 62,134 participants, a more than
1800-fold difference.
One might hypothesize that part of the reason for
the discrepancy in study size cited and number of
cited studies to justify RCTs both within and between
medical fields may have to do with trends for RCT
sizes in each field. In other words, one might
hypothesize that Internal Medicine RCTs are typically
larger and performed more frequently than Ophthal-
mology or ENT studies, and this may explain part of
the differences. In order to study this, we standardized
both cited study number and cited study size by the
RCT “N” or number enrolled. These data are provided
in Table 3. As can be seen in columns 5 and 6, this
standardization does explain some of the between-
specialty differences. For example, standardized study
size cited/N enrolled (column 5) shows converging
values for Ophthalmology, OB-GYN, Psychiatry, and
General Surgery. In the final column, total numbers of
studies cited are standardized by N enrolled, and con-
verging values are found for ENT, Internal Medicine,
OB-GYN, and Ophthalmology. While standardizing in
this fashion explains some between-specialty differ-
ences, there is still much discrepancy remaining, and
not all of the within-specialty discrepancies can be
accounted for by standardization.
Discussion
Randomized clinical trials (RCTs) provide results that
form the backbone of modern medical practice. Because
their results are so important, it is not surprising that
their conduct and reporting are highly standardized. The
CONSORT Statement [5] is an internationally recog-
nized guide to the conduct and reporting of RCTs. The
statement includes recommendations for all aspects of
RCT conduct and reporting, such as inclusion criteria,
randomization, stopping rules, and analysis.
However, the justification for why we conduct RCTs is
not evidence-based. There is no Prestudy CONSORT or
equivalent guide that recommends the level of evidence
needed to conduct an RCT in the first place. Some RCTs
are conducted after a rigorous analysis of many
evidence-based observational studies and small prelimin-
ary clinical trials. Others are conducted based on case
series and expert opinion.
Our study has quantified the wide discrepancy in
evidence that is used to justify the conduct of RCTs. We
randomly compared this evidence across six medical
areas and within these areas as well. We randomly
Fig. 2 Average size of study cited stratified by specialty
Table 3 Average cited study size and average number of studies cited standardized by RCT size








Ophthalmology 1060 1167 10.0 1.10 0.009
OB-GYN 618 1099 4.8 1.78 0.008
Psychiatry 347 530 4.8 1.53 0.014
ENT 2712 399 4.5 0.15 0.002
General Surgery 362 482 8.8 1.33 0.024
Internal Medicine 1192 3238 7.5 2.72 0.006
N number, RCT randomized controlled trial, OB-GYN Obstetrics and Gynecology, ENT Otorhinolaryngology
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picked approximately 25 papers per specialty and stud-
ied the justification explanation in the Introduction of
each RCT. We tabulated the number of studies that jus-
tified each RCT, the size of the studies that were used to
justify the RCT, and the type of study as well (including
cited expert opinion).
Although the discrepancies found to justify RCTs
were large across all outcomes studied, Table 2 sum-
marizes the large discrepancy found when looking at
type of study cited to justify RCTs. Across specialties
there is a large range of study types used to justify
RCTs. The only area where there is reasonable conver-
gence is previous RCTs cited (range 1.85–3.64). For all
other study types there is a large range of study num-
bers used to justify an RCT. The mix of studies used
to justify RCTs also varies widely. Finally, the large
standard deviations in Table 2 (often the standard
deviations are larger than the mean) show that dis-
crepancies justifying RCTs are even larger within spe-
cialties than they are across specialties.
Since systematic reviews and meta-analyses are used
to synthesize existing evidence available for a particular
treatment or intervention and identify potential gaps
where future research is needed, naturally, they are use-
ful and necessary for justifying the conduct of an RCT
[7]. However, many researchers often fail to consider the
results of relevant systematic reviews when designing
their RCTs [8]. Our study found that RCTs did not con-
sistently have systematic reviews or meta-analyses cited
as a justification for the study to be conducted since
there were large discrepancies both between and within
specialties. A previous study looking at trials published
in leading medical journals in 2007 found that, in the
Introduction section of each trial, 56% of trials referred
to at least one previous individual trial, 22% referred to
at least one meta-analysis, and 7% referred to at least
one systematic review [9]. In contrast, Cooper at al.
found that 33% of trials had used a systematic review to
influence their study design, but this difference may have
been due to Cooper et al. only including trials that had a
relevant Cochrane review available in the literature [10].
Potential limitations of our study include a lack of
classification of RCTs and the number of RCTs included.
In our study, we did not distinguish between RCTs that
were clinical trials from different phases. Although all
studies we included were randomized, different clinical
trial phases are intended to answer different research
questions, so their justification to be conducted may also
be different. For example, some phase III trials are
intended to determine the efficacy of a new treatment
compared to the standard treatment, while some phase
II trials are intended to determine the optimal dose
while balancing toxicity and efficacy [11]. At earlier
phases, different types and levels of evidence may be
available to justify the conduct of an RCT [11], but this
was not taken into account in our study. However, the
differences and progression between different clinical
trial phases are not always clearly defined or consistent
[12], so treating RCTs as one large group may be the
best possible way to study the issue of RCT justification.
The number of studies included is also a potential
limitation, as only 148 RCTs were included in the ana-
lysis. There are many other RCTs available in the litera-
ture, so the sample size may not have been large
enough, and the results of this study should be consid-
ered exploratory. This may also be another reason why
the standard deviations were so large in the analysis.
However, randomization was used to select studies in
order to prevent potential bias in selecting RCTs.
Conclusions
Because the use of RCTs is so widespread in modern
medicine, we feel that the reasons justifying RCTs should
also be more convergent. Since the justification for
conducting RCTs varies widely both within and across
specialties, there is a need for a set of guidelines to be
developed in order to help investigators decide when there
is sufficient evidence to conduct an RCT. This is an area
that researchers, clinicians, and policy makers should
work toward together in the not too distant future.
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